Search results

  1. J

    Low-dose naltrexone as a treatment for chronic fatigue syndrome, 2020, Bolton, Chapman, Van Marwijk

    Quite honestly, I don’t consider this hype: seems like a pretty measured comment to me. Please note that if you want to wait for a RCT study on LDN to be funded, conducted, have data analyzed and published, please be prepared to wait at least 5 years.
  2. J

    Trial of CT38 for ME/CFS by Cortene Inc.: big claims being made...

    Here is the link to the newsletter https://cortene.wordpress.com/2020/01/ I don't think that they would be proceeding if the drug had demonstrated no positive effect.
  3. J

    An investigation into the modulation of T cell phenotypes by amitriptyline and nortriptyline, 2019, Conroy et al

    Interesting. I remember discussion about amitrip. on the Howard Bloom thread here—the MECFS guy that does 700 pushups.
  4. J

    VDAC oligomers form mitochondrial pores to release mtDNA fragments and promote lupus-like disease, 2019, Kim et al

    https://www.cell.com/cell-metabolism/pdfExtended/S1550-4131(18)30573-4 Preserving Insulin Secretion in Diabetes by Inhibiting VDAC1 Overexpression and Surface Translocation in b Cells Haven’t read either, but wonder if oligomerization results from overexpression.
  5. J

    Ron Davis latest: more evidence of "something in the blood" (Simon M blog)

    Sh*t—well it is still under consideration for macular degeneration—phase 2.
  6. J

    Perturbation of effector and regulatory T cell subsets in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) (2019) Karhan, Unutmaz et al

    Thanks. But T cells still come back after Campath treatment. These new T cells are less likely to be “problematic” like the old ones were because the reconstituted T cells are different/better? https://www.jimmunol.org/content/191/12/5867...
  7. J

    Perturbation of effector and regulatory T cell subsets in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) (2019) Karhan, Unutmaz et al

    Lemtrada underwent review by EMA, who restricted use—final approval by EC pending. https://www.ema.europa.eu/en/medicines/human/referrals/lemtrada https://medshadow.org/ms-drug-restricted-in-europe/ https://pharmaphorum.com/news/european-regulator-restricts-use-of-sanofi-ms-drug-lemtrada/...
  8. J

    Perturbation of effector and regulatory T cell subsets in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) (2019) Karhan, Unutmaz et al

    @Jonathan Edwards Campath-1H is less dangerous in your opinion than cyclophosphamide? Also what is the difference between Campath-1H (humanized) and Alemtuzumab? Thanks
  9. J

    Perturbation of effector and regulatory T cell subsets in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) (2019) Karhan, Unutmaz et al

    So maybe there might be some benefit to wiping out abnormal T cells with cyclophosphamide.....
  10. J

    PEM is associated with greater symptom burden and psychological distress in patients ... with CFS (2019) May, Fletcher, Klimas et al.

    Really poor use of nine people’s time. Any funding and salary time devoted to this should have/could have been devoted to science-based science.
  11. J

    Open Medicine Foundation (OMF) fundraising

    I would assume the difficulty is in getting MECFS brain cells, not just brain cells per se. Maybe they could induce MECFS in the cells with Cipro or the anti-cancer compounds that @RDP mentioned in other threads
  12. J

    JAK Inhibitor Improves Patient-Reported Outcomes in RA

    https://www.medpagetoday.org/rheumatology/arthritis/83966?_ga=2.265148431.1072804894.1576686559-674435307.1570713348 Journal article here https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-019-2059-8 Looks like vitality and insomnia improved on this.
  13. J

    Open Medicine Foundation (OMF) fundraising

    Yeah brain cells too. But they would need to get cells from MECFS patients. First cell culture of live adult human neurons shows potential of brain cell types https://www.sciencedaily.com/releases/2017/01/170117141149.htm
  14. J

    Open Medicine Foundation (OMF) fundraising

    Anybody know if this is an established technique/method? Thanks
  15. J

    ME/CFS patients exhibit altered T cell metabolism and cytokine associations (2019) Mandarano, Hanson et al

    Ok but how does this altered T cell metabolism affect brain stem function as shown in other research?
  16. J

    Ron Davis latest: more evidence of "something in the blood" (Simon M blog)

    @Badpack Is it possible that the plasmapheresis did not remove the “bad stuff” (exosomes) because they were not the right size? I assume that plasma filters are designed to remove specific size antibodies and maybe the “something in the plasma” was too small to be removed by the filters?
  17. J

    Stem cell transplant 'game changer' for MS patients

    https://www.google.com/amp/s/www.the-scientist.com/news-opinion/northwestern-university-stem-cell-therapy-clinic-closes-abruptly--66401/amp Hmmmm
  18. J

    When a DNA Test Says You’re a Younger Man, Who Lives 5,000 Miles Away, NY Times

    https://www.nytimes.com/2019/12/07/us/dna-bone-marrow-transplant-crime-lab.html Interesting... wonder if pwmecfs could benefit from a bone marrow transplant, especially since all of the blood will have the donor’s genotype. In other words, maybe the blood after transplant won’t have...
Back
Top Bottom